HIV/AIDS Diagnostics Market

HIV/AIDS Diagnostics Market (Product: Kits and Reagents and Instruments; and Test Type: Nucleic Acid Tests, Rapid Tests, ELISA, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global HIV/AIDS Diagnostics Market Outlook 2031

  • The global industry was valued at US$ 4.0 Bn in 2021
  • It is projected to advance at a CAGR of 9.3% from 2022 to 2031 and reach more than US$ 9.6 Bn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of HIV/AIDS is expected to propel the HIV/AIDS diagnostics market size during the forecast period. HIV/AIDS tests identify antibodies in blood or oral fluids. Most assays that are used to detect Nucleic Acids (NAT) are complex and technically demanding.

Increase in awareness about HIV/AIDS diagnosis is expected to augment market expansion in the near future. Over-the-counter HIV self-tests are gaining traction, as they help overcome the stigma associated with HIV testing. R&D of new diagnostic technologies is likely to offer lucrative growth opportunities for vendors in the industry. Key players are launching advanced rapid diagnostic tests in order to increase their HIV/AIDS diagnostics market share.

Hiv Aids Diagnostics Market

Market Introduction

Human Immunodeficiency Virus (HIV) is a virus that attacks the immune system, specifically CD4 cells (T cells). Untreated HIV can lead to Acquired Immunodeficiency Syndrome (AIDS), a condition in which the immune system is severely damaged and incapable of fighting infections and diseases.

HIV is primarily transmitted through the exchange of bodily fluids such as blood, semen, vaginal secretions, and breast milk. Sexual contact, injection drug use, and mother-to-child transmission (during birth or breastfeeding) are the most common modes of transmission.

HIV can also be transmitted through the use of contaminated needles or equipment for tattooing, body piercing, or acupuncture. Organ transplantation or blood transfusion can also transmit HIV to a recipient. Stringent screening of blood and organ donors can limit this type of transmission.

Request a sample to get extensive insights into the HIV/AIDS Diagnostics Market

Rise in Prevalence of HIV/AIDS Driving HIV/AIDS Diagnostics HIV/AIDS Diagnostics Market Development

The ongoing global HIV/AIDS epidemic and the need for accurate disease diagnosis and monitoring are estimated to boost the demand for HIV/AIDS diagnostics. According to the World Health Organization (WHO), approximately 38.8 million people worldwide suffered from HIV in 2021. The number of cases is increasing steadily, as the virus continues to spread. As per the Centers for Disease Control and Prevention (CDC), around 38,000 new HIV infections were reported in the U.S. in 2019.

According to the same source, HIV affects certain groups disproportionately in the U.S., including men who have had intercourse with men, people who inject drugs, and transgender women. In 2019, it was estimated that approximately 1.2 million people in the country were living with HIV, with men constituting the vast majority. Thus, high incidence of HIV/AIDS is anticipated to contribute to HIV/AIDS diagnostics market growth in the near future.

Increase in Testing for HIV/AIDS

Development of new diagnostic technologies and surge in accessibility of testing in emerging economies are expected to offer lucrative growth opportunities for vendors in HIV/AIDS diagnostics industry. Key players are launching advanced products such as rapid tests and nucleic acid-based assay (Simple Amplification-based Assay (SAMBA) to broaden their customer base.

Implementation of POC diagnostic standards is also expected to augment the market size in the next few years. According to the WHO, an ideal POC diagnostic must be Affordable, Sensitive, Specific, User-friendly, Rapid/Robust, Equipment-free, and Deliverable (ASSURED). As per the WHO, in 2021, approximately 76% of people living with HIV globally were aware of their HIV-positive status. This represents an increase from previous years and demonstrates the success of efforts to raise awareness and testing for HIV/AIDS.

Implementation of HIV testing programs in several healthcare settings has led to a significant rise in awareness about the disease and testing of HIV/AIDS. These programs are designed to increase the number of people being tested for HIV and make testing more accessible.

The CDC recommends that everyone between the ages of 13 and 64 be tested for HIV at least once as part of routine health care. It also encourages more frequent testing for those at higher risk of HIV infection. According to the CDC, approximately 85% of people living with HIV in the U.S. received an HIV diagnosis in 2019.

According to the European Centre for Disease Prevention and Control (ECDC), in 2021, approximately 78% of HIV-positive people in the European Union and the European Economic Area were aware of their HIV status. This can be ascribed to the successful efforts of various governments in Europe to raise HIV/AIDS awareness and testing in the region. Thus, growth in awareness about HIV/AIDS is projected to boost the HIV/AIDS diagnostics market progress in the near future.

Request a custom report on HIV/AIDS Diagnostics Market

Extensive Usage of Diagnostic Instruments

According to the latest HIV/AIDS diagnostics market trends, the instruments product segment held major share of the industry in 2021. Rise in number of HIV patients is expected to drive the demand for HIV diagnostic instruments.

HIV diagnostic testing employs a variety of instruments, including ELISA and Western Blot. Some instrument-based tests, such as Polymerase Chain Reaction (PCR), are extremely sensitive and can detect very low levels of HIV in a person's blood.

Vendors in the HIV/AIDS diagnostics business are launching new products in the instruments product segment. In August 2022, Molbio Diagnostics launched the Truenat RT-PCR Test for HIV diagnosis. Truenat is a portable, battery-powered, IoT-enabled, real-time PCR platform for Point-of-Care (POC) testing with a sample-to-result time of less than an hour.

Rapid HIV Tests Gaining Traction

Based on test type, the rapid tests (POC) segment is likely to dominate the industry during the forecast period, as per the latest HIV/AIDS diagnostics market analysis. Rapid HIV tests can be performed at POC, which is a more convenient option for patients than having to go to a separate laboratory. Furthermore, rapid tests are less expensive than traditional laboratory tests.

Regional Outlook

North America is expected to hold the largest share of the HIV/AIDS diagnostics industry during the forecast period. The region dominated the market with 30.0% share in 2021. Increase in incidence of HIV/AIDS, presence of key vendors, and rise in investment in R&D are boosting market statistics in the region. 

The industry in Asia Pacific is projected to grow at the fastest rate during the forecast period due to high incidence of HIV/AIDS in the region.

Analysis of Key Players

The global industry is fragmented, with the presence of a large number of vendors. Most of the companies are increasing their market share through significant investment in R&D of new tests. Expansion of product portfolio and mergers & acquisitions are key strategies adopted by vendors.

Hologic, Inc. Abbott, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., OraSure Technologies, Inc., Siemens Healthcare GmbH, Chembio Diagnostics, Inc., Danaher Corporation, and Becton, Dickinson and Company are prominent market entities.

Each of these players has been profiled in the market report based on parameters such as company overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in HIV/AIDS Diagnostics Market

  • In November 2022, Abbott introduced the Panbio HIV Self-Test for more reliable and discrete testing at home
  • In December 2021, F. Hoffmann-La Roche Ltd. launched the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries that accept the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit.
  • In November 2020, Alere announced the launch of its HIV 1/2 Detect test, a rapid diagnostic test that can provide results in as little as 15 minutes

Global HIV/AIDS Diagnostics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 4.0 Bn

Market Forecast Value in 2031

More than US$ 9.6 Bn

Growth Rate (CAGR)

9.3%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Kits and Reagents
    • Instruments
  • Test Type
    • Nucleic Acid Tests
    • Rapid Tests (POC)
    • ELISA
    • Others
  • End-user
    • Hospitals
    • Diagnostic Laboratories
    • Academic and Research Institutes
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand

Companies Profiled

  • Hologic, Inc.
  • Abbott
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • OraSure Technologies, Inc.
  • Siemens Healthcare GmbH
  • Chembio Diagnostics, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global HIV/AIDS diagnostics market in 2021?

It was valued at US$ 4.0 Bn in 2021.

How big will the industry be in 2031?

It is projected to reach more than US$ 9.6 Bn by 2031.

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 9.3% from 2022 to 2031.

Which are the prominent trends that affect business growth?

Rise in prevalence of HIV/AIDS and increase in awareness about HIV/AIDS diagnosis.

Which region will account for major share during the forecast period?

North America is likely to account for major share from 2022 to 2031.

Who are the prominent players operating in the sector?

Hologic, Inc. Abbott, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., OraSure Technologies, Inc., Siemens Healthcare GmbH, Chembio Diagnostics, Inc., Danaher Corporation, and Becton, Dickinson and Company.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global HIV/AIDS Diagnostics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global HIV/AIDS Diagnostics Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projection (US$ Mn)

            4.4.2. Market Volume/Unit Shipments Projection

        4.5. Porter’s Five Forces Analysis

    5. Key Insights

        5.1. HIV Disease Epidemiology

        5.2. Technological Advancements

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)

    6. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Product

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Product, 2017–2031

            6.3.1. Kits and Reagents

            6.3.2. Instruments

        6.4. Market Attractiveness Analysis, by Product

    7. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Test Type

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Test Type, 2017–2031

            7.3.1. Nucleic Acid Tests

            7.3.2. Rapid Tests (POC)

            7.3.3. ELISA

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Test Type

    8. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Diagnostic Laboratories

            8.3.3. Academic and Research Institutes

            8.3.4. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America HIV/AIDS Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product, 2017–2031

            10.2.1. Kits and Reagents

            10.2.2. Instruments

        10.3. Market Value Forecast, by Test Type, 2017–2031

            10.3.1. Nucleic Acid Tests

            10.3.2. Rapid Tests (POC)

            10.3.3. ELISA

            10.3.4. Others

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals

            10.4.2. Diagnostic Laboratories

            10.4.3. Academic and Research Institutes

            10.4.4. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Product

            10.6.2. By Test Type

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe HIV/AIDS Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Kits and Reagents

            11.2.2. Instruments

        11.3. Market Value Forecast, by Test Type, 2017–2031

            11.3.1. Nucleic Acid Tests

            11.3.2. Rapid Tests (POC)

            11.3.3. ELISA

            11.3.4. Others

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals

            11.4.2. Diagnostic Laboratories

            11.4.3. Academic and Research Institutes

            11.4.4. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Product

            11.6.2. By Test Type

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific HIV/AIDS Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017–2031

            12.2.1. Kits and Reagents

            12.2.2. Instruments

        12.3. Market Value Forecast, by Test Type, 2017–2031

            12.3.1. Nucleic Acid Tests

            12.3.2. Rapid Tests (POC)

            12.3.3. ELISA

            12.3.4. Others

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals

            12.4.2. Diagnostic Laboratories

            12.4.3. Academic and Research Institutes

            12.4.4. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Product

            12.6.2. By Test Type

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America HIV/AIDS Diagnostics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017–2031

            13.2.1. Kits and Reagents

            13.2.2. Instruments

        13.3. Market Value Forecast, by Test Type, 2017–2031

            13.3.1. Nucleic Acid Tests

            13.3.2. Rapid Tests (POC)

            13.3.3. ELISA

            13.3.4. Others

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals

            13.4.2. Diagnostic Laboratories

            13.4.3. Academic and Research Institutes

            13.4.4. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Product

            13.6.2. By Test Type

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa HIV/AIDS Diagnostics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017–2031

            14.2.1. Kits and Reagents

            14.2.2. Instruments

        14.3. Market Value Forecast, by Test Type, 2017–2031

            14.3.1. Nucleic Acid Tests

            14.3.2. Rapid Tests (POC)

            14.3.3. ELISA

            14.3.4. Others

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals

            14.4.2. Diagnostic Laboratories

            14.4.3. Academic and Research Institutes

            14.4.4. Others

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Product

            14.6.2. By Test Type

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company (2021)

        15.3. Company Profiles

            15.3.1. Hologic, Inc

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Abbott

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Bio-Rad Laboratories, Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. F. Hoffmann-La Roche Ltd.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. OraSure Technologies, Inc.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

            15.3.6. Siemens Healthcare GmbH

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

            15.3.7. Chembio Diagnostics, Inc.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

            15.3.8. Danaher Corporation

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

            15.3.9. Becton, Dickinson and Company

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

    List of Tables

    Table 01: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 02: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 03: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 07: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 08: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 11: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 12: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 15: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 16: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 17: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 19: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 20: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 23: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 24: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Market Share, By Product

    Figure 02: Market Share, By Test Type

    Figure 03: Market Share, By End-user

    Figure 04: Market Share, By Region

    Figure 05: Figure 05: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 06: Figure 06: Global HIV/AIDS Diagnostics Market Value Share, by Product (2021)

    Figure 07: Figure 07: Global HIV/AIDS Diagnostics Market Value Share, by End-user (2021)

    Figure 08: Global HIV/AIDS Diagnostics Market Value Share, by Test Type (2021)

    Figure 09: Global HIV/AIDS Diagnostics Market Value Share, by Region (2021)

    Figure 10: Global HIV/AIDS Diagnostics Market Value Share Analysis, by Product, 2021 and 2031

    Figure 11: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Kits and Reagents, 2017–2031

    Figure 12: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Instruments, 2017–2031

    Figure 13: Global HIV/AIDS Diagnostics Market Attractiveness, by Product, 2022–2031

    Figure 14: Global HIV/AIDS Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 15: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Nucleic Acid Tests, 2017–2031

    Figure 16: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Rapid Tests (POC), 2017–2031

    Figure 17: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by ELISA, 2017–2031

    Figure 18: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 19: Global HIV/AIDS Diagnostics Market Attractiveness, by Test Type, 2022–2031

    Figure 20: Global HIV/AIDS Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 21: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Hospitals, 2017–2031

    Figure 22: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories, 2017–2031

    Figure 23: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Academic and Research Institutes, 2017–2031

    Figure 24: Global HIV/AIDS Diagnostics Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 25: Global HIV/AIDS Diagnostics Market Attractiveness, by End-user, 2022–2031

    Figure 26: Global HIV/AIDS Diagnostics Market Value Share Analysis, by Region, 2021 and 2031

    Figure 27: Global HIV/AIDS Diagnostics Market Attractiveness, by Region, 2022-2031

    Figure 28: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 29: North America HIV/AIDS Diagnostics Market Value Share (%), by Country, 2021 and 2031

    Figure 30: North America HIV/AIDS Diagnostics Market Attractiveness, by Country, 2022–2031

    Figure 31: North America HIV/AIDS Diagnostics Market Value Share Analysis, by Product, 2021 and 2031

    Figure 32: North America HIV/AIDS Diagnostics Market Attractiveness, by Product, 2022–2031

    Figure 33: North America HIV/AIDS Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 34: North America HIV/AIDS Diagnostics Market Attractiveness, by Test Type, 2022–2031

    Figure 35: North America HIV/AIDS Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 36: North America HIV/AIDS Diagnostics Market Attractiveness, by End-user, 2022–2031

    Figure 37: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 38: Europe HIV/AIDS Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 39: Europe HIV/AIDS Diagnostics Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 40: Europe HIV/AIDS Diagnostics Market Value Share Analysis, by Product, 2021 and 2031

    Figure 41: Europe HIV/AIDS Diagnostics Market Attractiveness, by Product, 2022–2031

    Figure 42: Europe HIV/AIDS Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 43: Europe HIV/AIDS Diagnostics Market Attractiveness, by Test Type, 2022–2031

    Figure 44: Europe HIV/AIDS Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 45: Europe HIV/AIDS Diagnostics Market Attractiveness, by End-user, 2022–2031

    Figure 46: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 47: Asia Pacific HIV/AIDS Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 48: Asia Pacific HIV/AIDS Diagnostics Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 49: Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by Product, 2021 and 2031

    Figure 50: Asia Pacific HIV/AIDS Diagnostics Market Attractiveness, by Product, 2022–2031

    Figure 51: Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 52: Asia Pacific HIV/AIDS Diagnostics Market Attractiveness, by Test Type, 2022–2031

    Figure 53: Asia Pacific HIV/AIDS Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 54: Asia Pacific HIV/AIDS Diagnostics Market Attractiveness, by End-user, 2022–2031

    Figure 55: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 56: Latin America HIV/AIDS Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 57: Latin America HIV/AIDS Diagnostics Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 58: Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by Product, 2021 and 2031

    Figure 59: Latin America HIV/AIDS Diagnostics Market Attractiveness, by Product, 2022–2031

    Figure 60: Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 61: Latin America HIV/AIDS Diagnostics Market Attractiveness, by Test Type, 2022–2031

    Figure 62: Latin America HIV/AIDS Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 63: Latin America HIV/AIDS Diagnostics Market Attractiveness, by End-user, 2022–2031

    Figure 64: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 65: Middle East & Africa HIV/AIDS Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 66: Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 67: Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by Product, 2021 and 2031

    Figure 68: Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness, by Product, 2022–2031

    Figure 69: Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 70: Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness, by Test Type, 2022–2031

    Figure 71: Middle East & Africa HIV/AIDS Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 72: Middle East & Africa HIV/AIDS Diagnostics Market Attractiveness, by End-user, 2022–2031

    Figure 73: Global HIV/AIDS Diagnostics Market Share Analysis, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved